Skip to main content
Clinical Trials/JPRN-jRCT2032220027
JPRN-jRCT2032220027
Recruiting
未知

A clinical study of the ultrasonic renal denervation system (PRDS-001) in patients with hypertension - RADIANCE-HTN DUO

Kai Hisashi0 sites154 target enrollmentApril 16, 2022
ConditionsHypertension

Overview

Phase
未知
Intervention
Not specified
Conditions
Hypertension
Sponsor
Kai Hisashi
Enrollment
154
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 16, 2022
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Kai Hisashi

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients who have received antihypertensive treatment with two antihypertensive drugs for at least 4 weeks prior to obtaining consent, with no change in the type or dosage
  • 2\. Patients with a mean seated office blood pressure of between 140 mmHg and 180 mmHg systolic and between 90 mmHg and 110 mmHg diastolic at screening visit
  • 3\. Patients with a mean 24\-hour ABPM (ambulatory blood pressure measurement) of between 130 mmHg and 170 mmHg systolic and between 80 mmHg and 105 mmHg diastolic at baseline visit

Exclusion Criteria

  • 1\. Lacks appropriate renal artery anatomy for renal denervation
  • 2\. Secondary hypertension other than sleep apnea
  • 3\. Type 1 diabetes mellitus or uncontrolled Type 2 diabetes
  • 4\. Any history of cerebrovascular event or severe cardiovascular event, within 6 months prior to consent
  • 5\. Repeated hospitalization for hypertensive crisis (twice or more) within 12 months prior to obtaining consent, or any hospitalization for hypertensive crisis within 3 months prior to obtaining consent
  • 6\. Patients prescribed to drugs that have antihypertensive effects for other chronic diseases, and the investigator considers that discontinuation of these drugs may pose a serious risk to health
  • 7\. Patients who are taking drugs known to affect blood pressure and the investigator judges that it is not possible to discontinue these drugs during the study period
  • 8\. Patients with a history of persistent or permanent atrial tachyarrhythmia
  • 9\. Patients with active implantable medical devices
  • 10\. Primary pulmonary hypertension

Outcomes

Primary Outcomes

Not specified

Similar Trials